Evidence map›Paper›PMID 27834938›Full record

ArticleBlood cancer journal2016

Overexpression of RANKL by invariant NKT cells enriched in the bone marrow of patients with multiple myeloma.

E Spanoudakis, M Papoutselis, E Terpos, M A Dimopoulos, C Tsatalas, D Margaritis, A Rahemtulla, I Kotsianidis, A Karadimitris

Open access · goldAbstract readLetter
PubMed Full text at PMC Publisher
In one paragraph

Article in Blood cancer journal, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.9field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 15 citations in OpenAlex.

  1. LILRB4 on multiple myeloma cells promotes bone lesion by p-SHP2/NF-κB/RELT signal pathway.Journal of experimental & clinical cancer research : CR · 2024
    Article
  2. The pathophysiology of immunoporosis: innovative therapeutic targets.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2021
    Review
  3. Immunological Prognostic Factors in Multiple Myeloma.International journal of molecular sciences · 2021
    Review
  4. Review
  5. Immunoporosis: A New Role for Invariant Natural Killer T (NKT) Cells Through Overexpression of Nuclear Factor-κB Ligand (RANKL).Medical science monitor : international medical journal of experimental and clinical research · 2019
    Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 2 countries.

E SpanoudakisDepartment of Haematology, Democritus University of Thrace, Alexandroupolis, Greece.
M PapoutselisDepartment of Haematology, Democritus University of Thrace, Alexandroupolis, Greece.
E TerposDepartment of Clinical Therapeutics, University of Athens School of Medicine, Athens, Greece.
M A DimopoulosDepartment of Clinical Therapeutics, University of Athens School of Medicine, Athens, Greece.
C TsatalasDepartment of Haematology, Democritus University of Thrace, Alexandroupolis, Greece.
D MargaritisDepartment of Haematology, Democritus University of Thrace, Alexandroupolis, Greece.
A RahemtullaCentre for Haematology, Department of Medicine, Hammersmith Hospital, Imperial College London, London, UK.
I KotsianidisDepartment of Haematology, Democritus University of Thrace, Alexandroupolis, Greece.
A KaradimitrisCentre for Haematology, Department of Medicine, Hammersmith Hospital, Imperial College London, London, UK.ORCID 0000-0002-9566-9780
Democritus University of Thrace · GRHammersmith Hospital · GBNational and Kapodistrian University of Athens · GR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

AdultAgedAged, 80 and overBone MarrowBone Marrow CellsFemaleGene Expression Regulation, NeoplasticHumansMaleMiddle AgedMultiple MyelomaNatural Killer T-CellsRANK LigandUp-RegulationRANK LigandTNFSF11 protein, human

Identifiers

PMID27834938
PMCPMC5148055
OpenAlexW2552592374

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.